RESTORING IMMUNE TOLERANCE
Allero Therapeutics develops novel non-invasive and patient-friendly next generation immunotherapies for immune mediated disorders like autoimmune -, allergic diseases and ADA (anti-drug antibodies). Its proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology is designed to induce long-lasting antigen-specific immune tolerance.
Allero Therapeutics is a biolech company that develops next generation immunotherapies for immune disorders like autoimmune -, allergic diseases, and ADA (anti-drug antibodies).
Based on ideas of the founders, the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.
Allero started to develop an R&D pipeline with a focus on a celiac disease product and a food allergy product, and we are looking for other pipeline opportunities to be developed in partnerships.